Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy
- PMID: 10989270
- DOI: 10.1016/S0893-133X(00)00116-0
Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy
Abstract
This investigation of fluvoxamine and fluoxetine-norfluoxetine distributions in vivo at steady-state and of quantitative kinetics in brain and plasma after drug therapy interruption was performed by fluorine nuclear magnetic resonance spectroscopy (19F MRS), spectroscopic imaging (MRSI), and plasma HPLC on 12 subjects treated for depression. MRSI suggests a homogeneous distribution of 19F MRS visible fluvoxamine mainly in brain. Fluvoxamine steady-state brain concentrations (12 +/- 5 microM; n = 13) and brain-to-plasma concentration ratios (10 +/- 2; n = 12) were similar to those of combined fluoxetine-norfluoxetine (CF-norfluoxetine) (13 +/- 6 microM; n = 4 and 10 +/- 6; n = 4). Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2). Fluvoxamine brain-to-plasma-half-life-ratio was 2.2 +/- 0.3 (n = 4), contrarily to CF-norfluoxetine (1.0 +/- 0.3; n = 2). This study shows that quantitative pharmacokinetics in target organs by 19F MRS in vivo should prove useful for understanding and investigating outcome of treatment modifications and side effects.
Similar articles
-
Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.MAGMA. 2004 May;16(6):268-76. doi: 10.1007/s10334-004-0033-0. Epub 2004 Mar 23. MAGMA. 2004. PMID: 15042463
-
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.Am J Psychiatry. 2002 May;159(5):755-60. doi: 10.1176/appi.ajp.159.5.755. Am J Psychiatry. 2002. PMID: 11986128
-
19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.Am J Psychiatry. 1997 Apr;154(4):516-22. doi: 10.1176/ajp.154.4.516. Am J Psychiatry. 1997. PMID: 9090339 Clinical Trial.
-
Pharmacokinetics of selective serotonin reuptake inhibitors.Pharmacol Ther. 2000 Jan;85(1):11-28. doi: 10.1016/s0163-7258(99)00048-0. Pharmacol Ther. 2000. PMID: 10674711 Review.
-
Pharmacokinetics of the selective serotonin reuptake inhibitors.J Clin Psychiatry. 1992 Feb;53 Suppl:13-20. J Clin Psychiatry. 1992. PMID: 1531816 Review.
Cited by
-
First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod.Theranostics. 2023 Feb 5;13(4):1217-1234. doi: 10.7150/thno.77041. eCollection 2023. Theranostics. 2023. PMID: 36923535 Free PMC article.
-
Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement.J Mol Neurosci. 2005;27(1):29-42. doi: 10.1385/JMN:27:1:029. J Mol Neurosci. 2005. PMID: 16055945
-
Human models as tools in the development of psychotropic drugs.Dialogues Clin Neurosci. 2002 Dec;4(4):377-87. doi: 10.31887/DCNS.2002.4.4/cgilles. Dialogues Clin Neurosci. 2002. PMID: 22034241 Free PMC article.
-
G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression.Neuropsychopharmacology. 2024 Feb;49(3):561-572. doi: 10.1038/s41386-023-01727-9. Epub 2023 Sep 6. Neuropsychopharmacology. 2024. PMID: 37673966 Free PMC article.
-
Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes.Psychopharmacology (Berl). 2011 Jul;216(1):75-84. doi: 10.1007/s00213-011-2190-y. Epub 2011 Feb 8. Psychopharmacology (Berl). 2011. PMID: 21301813
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources